StockMarketWire.com - Pharmaceutical company Clinigen said it would be providing access to its acute lymphoblastic leukaemia chemotherapeutic treatment in the UK from the 6 April as part of the global exclusive licensing and distribution agreement with Porton Biopharma.

The agreement was previously announced on 16 April 2020.

'Erwinase is approved in the UK as a component of a chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukaemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase,' the company said.

'With the onboarding of Erwinase coming earlier than originally anticipated this will bring forward an expected investment in working capital in-line with our previous guidance of £10m - £20m,' it added.

'Given the proximity to the year end and staggered roll out across each territory this is not expected to have a material impact on current year profit expectations.'


At 8:26am: [LON:CLIN] Clinigen Group PLC share price was 0p at 683p



Story provided by StockMarketWire.com